

Difficult Glycemic Control in Relation to the Presence of Diabetes-Autoantibodies among Type 1 Diabetic Patients

Thesis

*Submitted for Partial Fulfillment of Master Degree in
Endocrinology & Metabolism*

By

Noha Yehia Mohammed
MB BCh

Supervised by

Professor Dr. Mohammed Saad Hamed

*Professor of Internal Medicine & Endocrinology
Ain Shams University*

Ass. Professor Dr. Merhan Samy Nasr

*Assistant Professor of Internal Medicine & Endocrinology
Ain Shams University*

Dr. Hanan Mahmoud Ali

*Lecturer of Internal Medicine & Endocrinology
Ain Shams University*

Faculty of Medicine
Ain shams University

2018

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

At first and foremost all praises and thanks to **"ALLAH"** who gave me the power to finish this work.

No words can ever express my deepest appreciation and gratitude to **Professor Dr. Mohammed Saad Hamed, Professor of Internal Medicine & Endocrinology**, Ain Shams University, for his outstanding kind support, precious suggestions and continuous guidance throughout all stages of this work.

I would like to thank **Dr. Merhan Samy Nasr, Assistant Professor of Internal Medicine & Endocrinology**, Ain Shams University, who was very kind, supportive and helpful throughout this project.

My great respect and thanks to **Dr. Hanan Mahmoud Ali, Lecturer of Internal Medicine & Endocrinology**, Ain Shams University, for her morals, scientific support and continuous encouragement that helped me to finish my job smoothly.

My deepest thanks are also to **Dr. Nesma Ali Ibrahim, Lecturer of Internal Medicine & Endocrinology**, Ain Shams University, for her close clinical supervision and kind help.

I am also deeply grateful to **my dear family**, for their great support and help offered throughout this study.

Noha Yehia

List of Contents

Title	Page No.
List of Tables	5
List of Figures	8
List of Abbreviations	11
Introduction	1
Aim of the Work.....	4
Review of Literature	
📖 Diabetes Mellitus	5
📖 Diabetes Autoantibodies	40
📖 Autoantibodies and Their Effect on the Glycemic Control	60
Patients and Methods	63
Results	76
Discussion	109
Summary	119
Conclusion.....	125
Recommendations	126
References	127
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Etiologic classification of MODY	12
Table (2):	Screening for diabetes and prediabetes in asymptomatic children and adults.....	22
Table (3):	Diagnosis of diabetes mellitus	23
Table (4):	Pharmacological therapy of diabetes	28
Table (5):	Insulin types and pharmacokinetics	30
Table (6):	Descriptive analysis for all studied patients as regarding demographic, anthropometric, clinical data and duration of diabetes mellitus	77
Table (7):	Descriptive analysis for all studied patients as regarding the number of insulin units used, laboratory data (FBS, 2HPP, HbA1C, Cpeptide) and the presence of diabetes autoantibodies	79
Table (8):	Descriptive analysis for the distribution of diabetes autoantibodies among Group II	81
Table (9):	Comparison between Group I and Group II as regarding demographic, anthropometric, clinical data and duration of developing diabetes mellitus.....	84
Table (10):	Comparison between Group I and Group II as regarding the number of insulin units used and the laboratory data (FBS, 2HPP, HbA1C, Cpeptide).....	86
Table (11):	Comparison between Group II a, II b and II c as regarding demographic, anthropometric, clinical data and duration of developing diabetes mellitus.....	88

List of Tables (cont...)

Table No.	Title	Page No.
Table (12):	Comparison between Group II a, II b and II c as regarding the number of insulin units used, laboratory data (FBS, 2HPP, HbA1C, Cpeptide).....	90
Table (13):	Comparison between patients with negative GADA and patients with positive GADA among Group II as regarding demographic, anthropometric, clinical data and duration of developing diabetes mellitus	92
Table (14):	Comparison between patients with negative GADA and patients with positive GADA among Group II as regarding the number of insulin units used and the laboratory data (FBS, 2HPP, HbA1C, Cpeptide)	95
Table (15):	Comparison between patients with negative ICA and patients with positive ICA among Group II as regarding demographic, anthropometric, clinical data and duration of developing diabetes mellitus	97
Table (16):	Comparison between patients with negative ICA and patients with positive ICA among Group II as regarding the number of insulin units used and the laboratory data (FBS, 2HPP, HbA1C, Cpeptide).....	99
Table (17):	Comparison between patients with negative IAA and patients with positive IAA among Group II as regarding demographic, anthropometric, clinical data and duration of developing diabetes mellitus	101

List of Tables (cont...)

Table No.	Title	Page No.
Table (18):	Comparison between patients with negative IAA and patients with positive IAA among Group II as regarding the number of insulin units used and the laboratory data (FBS, 2HPP, HbA1C, Cpeptide).....	102
Table (19):	Correlation between GADA, ICA and IAA with the other studied parameters	104
Table (20):	Logistic regression analysis for predictors of cases with positive Abs	108

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Polyol pathway.....	17
Figure (2):	Insulin activity profile.....	31
Figure (3):	Schematic representation showing <i>in vitro</i> trans-differentiation of insulin-producing cells IPC from mesenchymal stem cells.....	34
Figure (4):	Formation of memory Bcells and plasma cells	42
Figure (5):	Diabetes autoantibodies' mechanism of action.....	44
Figure (6):	Diagrammatic representation of half -life of immunoglobulins in the circulation.....	45
Figure (7):	Anti-GAD antibodies	48
Figure (8):	Stiff person syndrome Exaggerated lumbar lordosis	50
Figure (9):	Exaggerated lumbar lordosis and feet extensor posturing in the stiff man syndrome	51
Figure (10):	Mucosal-administered insulin protects from type 1 diabetes mellitus	57
Figure (11):	Biological effects of anti-CD3 antibodies on T cells.....	58
Figure (12):	Gender distribution of the study population.	78
Figure (13):	Percentage of Group I and Group II	80
Figure (14):	Percentage of Group II a, Group II b and Group II c	82

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (15):	Percentage of GADA positivity among Group II.	82
Figure (16):	Percentage of ICA positivity among Group II.	83
Figure (17):	Percentage of IAA positivity among Group II.	83
Figure (18):	Bar chart showing the duration of diabetes mellitus among Group I and Group II.	85
Figure (19):	Bar chart showing Insulin units in Group I and Group II.	87
Figure (20):	Bar chart showing HbA1c level in in Group I and Group II.	87
Figure (21):	Bar chart showing the duration of diabetes mellitus in Group II a, Group II b and Group II c.	89
Figure (22):	Bar chart showing HbA1c level in Group II a, Group II b and Group II c.	91
Figure (23):	Bar chart demonstrating the duration of DM in patients with negative GADA and those with positive GADA among Group II.	93
Figure (24):	Bar chart demonstrating the age in patients with negative GADA and those with positive GADA among Group II.	94
Figure (25):	Bar chart demonstrating the height in patients with negative GADA and those with positive GADA among Group II.	94

List of Figures (cont...)

Fig. No.	Title	Page No.
Figure (26):	Bar chart demonstrating HbA1c level in patients with negative GADA and those with positive GADA among Group II.	96
Figure (27):	Bar chart showing the duration of diabetes mellitus in patients with negative ICA and those with positive ICA among Group II.	98
Figure (28):	Bar chart showing HbA1c level in patients with negative ICA and those with positive ICA among Group II.	100
Figure (29):	Bar chart showing HbA1c level in patients with negative IAA and those with positive IAA among Group II.	103
Figure (30):	High significant negative correlation between GADA level and duration of diabetes mellitus.	105
Figure (31):	Significant positive correlation between GADA level and HbA1c level.	105
Figure (32):	Significant positive correlation between IAA level and HbA1c level.	106
Figure (33):	High significant positive correlation between GADA and ICA levels.	106
Figure (34):	High significant positive correlation between GADA and IAA levels.	107
Figure (35):	High significant positive correlation between ICA and IAA levels.	107

List of Abbreviations

Abb.	Full term
ACEIs	<i>Angiotensin-converting enzyme inhibitors</i>
ADA	<i>American Diabetes Association</i>
AGE	<i>Advanced glycosylation end products</i>
ARBs	<i>Angiotensin receptor blockers</i>
BMI	<i>Body mass index</i>
CDE	<i>Certified diabetes educator</i>
CSII	<i>Continuous subcutaneous insulin infusion</i>
DAA	<i>Diabetes autoantibodies</i>
DCCT	<i>Diabetes Control and Complications Trial</i>
DKA	<i>Diabetic ketoacidosis</i>
DM	<i>Diabetes mellitus</i>
DPP-4	<i>Dipeptidyl peptidase-4</i>
DSME	<i>Diabetes self-management education</i>
EASD	<i>European Association for the Study of Diabetes</i>
ELISA	<i>Enzyme Linked ImmunoSorbent Assay</i>
FPG	<i>Fasting Plasma Glucose</i>
GABA	<i>Gamma-AminoButyric Acid</i>
GADA	<i>Glutamic Acid Decarboxylase Autoantibodies</i>
GDM	<i>Gestational Diabetes mellitus</i>
GLP1	<i>Glucagon like peptide 1</i>
HbA1c	<i>Glycosylated hemoglobin</i>
HHS	<i>Hyperglycemic hyperosmolar state</i>
HLA	<i>Human leukocyte antigen</i>
HMG-CoA	<i>3-hydroxy-3-methyl-glutaryl-coenzyme A</i>
HNF-1α	<i>Hepatocyte nuclear factor 1alpha</i>
HNF-1β	<i>Hepatocyte nuclear factor 1beta</i>
HNF-4α	<i>Hepatocyte nuclear factor 4 alpha</i>
HOMA IR	<i>Homeostatic model assessment of insulin resistance</i>

List of Abbreviations (cont...)

Abb.	Full term
IAA	<i>Insulin Autoantibodies</i>
ICA	<i>Islet Cell Cytoplasmic Autoantibodies</i>
IDDM	<i>Insulin Dependent Diabetes Mellitus</i>
IPF1	<i>Insulin promotor factor 1</i>
LADA	<i>Latent Autoimmune Diabetes of Adults</i>
MDI	<i>Multiple daily injections</i>
MHC	<i>Major Histocompatibility Complex</i>
MODY	<i>Maturity Onset Diabetes of Young</i>
NOD mice	<i>Non obese diabetic mice</i>
NGSP	<i>National Glycohemoglobin Standardization Program</i>
OGTT	<i>Oral Glucose Tolerance Test</i>
RBS	<i>Random Blood Sugar</i>
SGLT-2	<i>Selective sodium glucose transporter-2</i>
SHBG	<i>Sex hormone binding globulin</i>
TDD	<i>Total daily dose</i>
TIA	<i>Transient ischemic attack</i>
WHO	<i>World Health Organization</i>
2HrPP	<i>2 hours postprandial blood glucose</i>

ABSTRACT

The present study revealed that the most common auto-antibody found in those patients was the GADA, it was found in 94.4% of patients, while ICA and IAA were found in 83.3% and 66.7 % respectively.

The present study also showed a high statistically significant positive correlation between GADA level and HbA1c levels ($r = 0.361^{**}$, $P=0.005$) on the other hand there was a highly statistically significant negative correlation between GADA level and the duration of diabetes mellitus ($r = -0.437^{**}$, $P=0.000$) also it revealed a statistically significant positive correlation between IAA level and HbA1c level ($r = 0.305^{*}$, $P=0.018$).

By doing the multivariate regression analyses we found that HbA1c level, total number of insulin units per day and the duration of developing diabetes mellitus were significant predictive factors for the presence of diabetes autoantibodies; ($P=0.007$), ($P=0.033$) and ($P=0.043$) respectively.

Keywords: Insulin Autoantibodies - Hepatocyte nuclear factor 4 alpha

INTRODUCTION

Diabetes mellitus is a clinic-laboratory syndrome characterized by chronic hyperglycemia due to defect in insulin secretion or action or both leading to disturbance of metabolism of carbohydrate, protein, fat, water and electrolytes.

Diabetes mellitus is the leading cause of chronic renal failure, lower limb amputations and adult blindness (***Gupta and Mukherjee, 2014***).

There are three main types of Diabetes mellitus: type 1 DM, type 2 DM and Gestational diabetes mellitus (***American Diabetes Association, 2017***).

An expert committee of the American Diabetes Association has recommended dividing type 1 DM into type 1A (immune-mediated) and type 1B (other forms of type 1 DM that include virus-triggered autoimmune response in which the immune system attacks virus-infected cells along with the beta cells in the pancreas (Coxsackie virus family or Rubella), genetic factors and idiopathic (***Imagawa et al., 2000***).

Autoantibodies are strongly associated with the development of type 1 diabetes mellitus. The appearance of autoantibodies to one or more of the auto-antigens (Glutamic acid decarboxylase 65, Islet cell cytoplasm, or Insulin) signals an autoimmune pathogenesis of β -cell killing (***Ziegler et al., 2013***).

Although their appearance does not follow a distinct pattern, the presence of multiple autoantibodies has the highest positive predictive value for type 1 diabetes mellitus (**Pihoker et al., 2005**).

It is widely recognized that the presence of two or more auto-antibodies has a high sensitivity and specificity for rapid progression to insulin dependency within 5 years and may help clarify the diagnosis in some patients (**Ziegler et al., 2013**). In cases in which no evidence of autoimmunity can be detected, the classification used is idiopathic type 1 DM (**American Diabetes Association, 2014**).

The autoantibodies that are associated with type 1 diabetes include (GAD65, ICA and IAA) (**Bingley, 2010**).

GADA65 is the most commonly detected autoantibodies in newly diagnosed type 1 diabetics, it is positive in 75% of patients at time of diagnosis (**Anna and Waytt, 2017**).

GADA is an autoantibody directed towards Glutamic acid decarboxylase GAD the enzyme that synthesizes gamma-amino-butyric acid GABA from glutamic acid, GAD is present in ‘GABA-ergic’ nerve cells and non-neural cells and organs such as the pancreas, where GABA is stored in synaptic-like vesicles in islet beta cells, GABA plays a role in the release of insulin, therefore the presence of GAD autoantibodies cause depleted insulin secretion (**Fiorina, 2013**).